Eli Lilly and Company
LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The compaā¦ read more
Healthcare
Drug ManufacturersāGeneral
53 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$989.94
Price+2.37%
$22.95
1Y
Price
Market Cap
$932.267b
Large
Price/Earnings 3y Avg5y Avg
35.2x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+47.3%
EBITDA Margin+37.4%
Net Profit Margin+15.2%
Free Cash Flow Margin+47.3%
EBITDA Margin+37.4%
Net Profit Margin+15.2%
Free Cash Flow MarginRevenue
$72.250b
+10.9%
1y CAGR+29.2%
3y CAGR+26.8%
5y CAGREarnings
$25.275b
+22.5%
1y CAGR+73.1%
3y CAGR+50.8%
5y CAGREPS
$28.15
+22.7%
1y CAGR+73.5%
3y CAGR+52.2%
5y CAGRBook Value
$31.198b
$116.576b
Assets$85.378b
Liabilities$43.370b
DebtDebt to Assets
37.2%
1.3x
Debt to EBITDAFree Cash Flow
$13.580b
+51.4%
1y CAGR+743.4%
3y CAGR+515.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company